PIK3CA and colorectal carcinoma: Given the complex nature of CRC and the heterogeneity of PI3K pathway alterations, combination therapies involving PI3K inhibitors with other targeted agents or chemotherapy drugs are being explored to improve treatment response and overcome resistance [340,341].